Carter et al. first discovered that the anti-apoptotic protein Bcl-2 plays a key role in the survival of CML stem cells and progenitor cells, making it an attractive CML target [111]. Here, BCL2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.